Christina M Wyatt1, Douglas Kitch, Samir K Gupta, Camlin Tierney, Eric S Daar, Paul E Sax, Belinda Ha, Kathleen Melbourne, Grace A McComsey. 1. *Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; †Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA; ‡Department of Medicine, Indiana University School of Medicine, Indianapolis, IN; §Department of Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; ‖Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ¶ViiV Healthcare, Research Triangle Park, NC; #Gilead Sciences, Foster City, CA; and **Department of Pediatrics, Case Western Reserve University, Cleveland, OH.
Abstract
BACKGROUND:Antiretroviral therapy (ART) is associated with improved kidney function; however, the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir disoproxil fumarate (TDF) has been associated with decreased kidney function and proteinuria. METHODS: We examined changes in urine protein:creatinine (UPCR) and urine albumin:creatinine (UACR) ratios in 245 ART-naive participants in A5202 randomized in a substudy toblinded NRTI (abacavir/lamivudine, ABC/3TC, n = 124 or TDF/emtricitabine, TDF/FTC, n = 121) with open-label protease inhibitor (PI) atazanavir/ritonavir or nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz. RESULTS: At baseline, 18% of participants had clinically significant proteinuria (UPCR ≥200 mg/g), and 11% had clinically significant albuminuria (UACR ≥30 mg/g). The prevalence of clinically significant proteinuria and albuminuria decreased from baseline to week 96 in all treatment groups. In intention-to-treat analyses, there was a significant effect of NRTI component on fold change in UPCR (P = 0.011) and UACR (P = 0.018) from baseline to week 96, with greater improvements in participants randomized to ABC/3TC. There was no significant effect of NNRTI/PI component on fold change in UPCR (P = 0.23) or UACR (P = 0.88), and no significant interactions between NRTI and NNRTI/PI components. CONCLUSIONS: In this prespecified secondary analysis, ART initiation was associated with improvements in proteinuria and albuminuria, with significantly greater improvements in participants randomized to ABC/3TC versus TDF/FTC. These are the first data from a randomized trial to suggest that initiation of TDF/FTC may not be associated with the same degree of improvement in proteinuria and albuminuria that have been reported with other regimens. Future studies should consider the long-term clinical significance of these findings.
RCT Entities:
BACKGROUND: Antiretroviral therapy (ART) is associated with improved kidney function; however, the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir disoproxil fumarate (TDF) has been associated with decreased kidney function and proteinuria. METHODS: We examined changes in urine protein:creatinine (UPCR) and urine albumin:creatinine (UACR) ratios in 245 ART-naive participants in A5202 randomized in a substudy to blinded NRTI (abacavir/lamivudine, ABC/3TC, n = 124 or TDF/emtricitabine, TDF/FTC, n = 121) with open-label protease inhibitor (PI) atazanavir/ritonavir or nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz. RESULTS: At baseline, 18% of participants had clinically significant proteinuria (UPCR ≥200 mg/g), and 11% had clinically significant albuminuria (UACR ≥30 mg/g). The prevalence of clinically significant proteinuria and albuminuria decreased from baseline to week 96 in all treatment groups. In intention-to-treat analyses, there was a significant effect of NRTI component on fold change in UPCR (P = 0.011) and UACR (P = 0.018) from baseline to week 96, with greater improvements in participants randomized to ABC/3TC. There was no significant effect of NNRTI/PI component on fold change in UPCR (P = 0.23) or UACR (P = 0.88), and no significant interactions between NRTI and NNRTI/PI components. CONCLUSIONS: In this prespecified secondary analysis, ART initiation was associated with improvements in proteinuria and albuminuria, with significantly greater improvements in participants randomized to ABC/3TC versus TDF/FTC. These are the first data from a randomized trial to suggest that initiation of TDF/FTC may not be associated with the same degree of improvement in proteinuria and albuminuria that have been reported with other regimens. Future studies should consider the long-term clinical significance of these findings.
Authors: Rebecca Scherzer; Michelle Estrella; Yongmei Li; Andy I Choi; Steven G Deeks; Carl Grunfeld; Michael G Shlipak Journal: AIDS Date: 2012-04-24 Impact factor: 4.177
Authors: Saskia M E Vrouenraets; Christoph A Fux; Ferdinand W N M Wit; Evian Fernandez Garcia; Kees Brinkman; Frans J Hoek; Jan P van Straalen; Hansjakob Furrer; Ray T Krediet; Peter Reiss Journal: Clin Nephrol Date: 2012-04 Impact factor: 0.975
Authors: Lynda Anne Szczech; Donald R Hoover; Joseph G Feldman; Mardge H Cohen; Stephen J Gange; Lisa Goozé; Nancy R Rubin; Mary A Young; Xiaotao Cai; Qiuhu Shi; Wei Gao; Kathryn Anastos Journal: Clin Infect Dis Date: 2004-09-27 Impact factor: 9.079
Authors: Lene Ryom; Amanda Mocroft; Ole Kirk; Signe W Worm; David A Kamara; Peter Reiss; Michael Ross; Christoph A Fux; Philippe Morlat; Olivier Moranne; Colette Smith; Jens D Lundgren Journal: J Infect Dis Date: 2013-02-04 Impact factor: 5.226
Authors: Lesley A Inker; Christina Wyatt; Rebecca Creamer; James Hellinger; Matthew Hotta; Maia Leppo; Andrew S Levey; Aghogho Okparavero; Hiba Graham; Karen Savage; Christopher H Schmid; Hocine Tighiouart; Fran Wallach; Zipporah Krishnasami Journal: J Acquir Immune Defic Syndr Date: 2012-11-01 Impact factor: 3.731
Authors: Lynda Anne Szczech; Carl Grunfeld; Rebecca Scherzer; Jesse A Canchola; Charles van der Horst; Stephen Sidney; David Wohl; Michael G Shlipak Journal: AIDS Date: 2007-05-11 Impact factor: 4.177
Authors: Andrew Reid; Wolfgang Stöhr; A Sarah Walker; Ian G Williams; Cissy Kityo; Peter Hughes; Andrew Kambugu; Charles F Gilks; Peter Mugyenyi; Paula Munderi; James Hakim; Diana M Gibb Journal: Clin Infect Dis Date: 2008-04-15 Impact factor: 9.079
Authors: Philip J Peters; David M Moore; Jonathan Mermin; John T Brooks; Robert Downing; Willy Were; Aminah Kigozi; Kate Buchacz; Paul J Weidle Journal: Kidney Int Date: 2008-07-09 Impact factor: 10.612
Authors: Robert C Kalayjian; Nora Franceschini; Samir K Gupta; Lynda A Szczech; Ezekiel Mupere; Ronald J Bosch; Marlene Smurzynski; Jeffrey M Albert Journal: AIDS Date: 2008-02-19 Impact factor: 4.177
Authors: Amit C Achhra; Amanda Mocroft; Michael Ross; Lene Ryom-Nielson; Anchalee Avihingsanon; Elzbieta Bakowska; Waldo Belloso; Amanda Clarke; Hansjakob Furrer; Gregory M Lucas; Matti Ristola; Mohammed Rassool; Jonathan Ross; Charurut Somboonwit; Shweta Sharma; Christina Wyatt Journal: Int J Antimicrob Agents Date: 2017-06-28 Impact factor: 5.283
Authors: Lene Ryom; Jens D Lundgren; Peter Reiss; Mike Ross; Ole Kirk; Christophe A Fux; Phillipe Morlat; Eric Fontas; Colette Smith; Stephane De Wit; Antonella d'Arminio Monforte; Wafaa El Sadr; Camilla Hatleberg; Andrew Phillips; Caroline Sabin; Matthew Law; Amanda Mocroft Journal: J Infect Dis Date: 2021-02-24 Impact factor: 5.226
Authors: Cindy J Bednasz; Charles S Venuto; Qing Ma; Eric S Daar; Paul E Sax; Margaret A Fischl; Ann C Collier; Kimberly Y Smith; Camlin Tierney; Edward P Acosta; Donald E Mager; Gene D Morse Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191
Authors: Sanjiv M Baxi; Rebecca Scherzer; Ruth M Greenblatt; Howard Minkoff; Anjali Sharma; Mardge Cohen; Mary A Young; Alison G Abraham; Michael G Shlipak Journal: AIDS Date: 2016-02-20 Impact factor: 4.177
Authors: Samir K Gupta; Eunice Yeh; Douglas W Kitch; Todd T Brown; Charles S Venuto; Gene D Morse; Belinda Ha; Kathleen Melbourne; Grace A McComsey Journal: J Antimicrob Chemother Date: 2017-07-01 Impact factor: 5.758
Authors: Lauren F Collins; Anandi N Sheth; C Christina Mehta; Susanna Naggie; Elizabeth T Golub; Kathryn Anastos; Audrey L French; Seble Kassaye; Tonya Taylor; Margaret A Fischl; Adaora A Adimora; Mirjam-Colette Kempf; Frank J Palella; Phyllis C Tien; Ighovwerha Ofotokun Journal: Clin Infect Dis Date: 2021-04-26 Impact factor: 20.999